An observational study of heparin administration and reversal during catheter ablation for atrial fibrillation (CA-AF).
Not Applicable
Completed
- Conditions
- Prevention of micro embolism during Catheter Ablation for atrial fibrillationCardiovascular - Other cardiovascular diseases
- Registration Number
- ACTRN12618001489280
- Lead Sponsor
- Philip Cumpston
- Brief Summary
Retrospective analysis of data collected during catheter ablation procedures showed that when the I-SDtat 1 activated clotting time device was used, an ACT of 300 or more could be achieved with a single dose of heparin. The ACT after a single dose of protamine was close to the pre-heparin ACT over 90% of the time
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 710
Inclusion Criteria
All patients presenting for catheter ablation for atrial fibrillation, or implantation of a left atrial occlusion device.
Exclusion Criteria
Known allergic response to heparin. In this case, heparin will not be used.
Known history of heparin induced thrombosis/thrombocytopenia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method